QDQ: Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer

Product code QDQ, “Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer” in FDA's classification database, is a Class II device type under 21 CFR 892.2090 (radiological computer-assisted detection and diagnosis software), reviewed by FDA's Radiology panel. FDA's 510(k) database lists 40 clearances under QDQ, 40 of them since 2011.
Updated Oct 29, 2026 · Clearances from FDA’s 510(k) database, as of Oct 29, 2026
Product code
QDQ
Regulation
21 CFR 892.2090
Class
II
Panel
Radiology
Clearances
40
Most recent
Sep 14, 2026
Median review, last 2 years
159 days
Third-party review
Not eligible
Implant
No

What it covers

A radiological computer assisted detection and diagnostic software for suspected lesions is an image processing device intended to aid in the detection, localization, and characterization of lesions suspicious for cancer on acquired medical images (e.g., mammography , MR, CT, ultrasound, radiography). The device detects, identifies and characterizes lesions suspicious for cancer based on features or information extracted from the images, and may provide information about the presence, location, and characteristics of the lesion to the user. Primary diagnostic and patient management decisions are made by the clinical user.

FDA’s definition of product code QDQ, from the Product Classification database.

Recent clearances

510(k)DeviceApplicantDecisionType
K261517qCT Lung (v1.0)Qure.Ai Technologies Pvt. , Ltd.Sep 14, 2026Traditional
K260898Transpara (2.1.0)Screenpoint Medical B.V.Aug 14, 2026Special
K260086CadAI-B DxBeamWorks, Inc.Aug 12, 2026Traditional
K260303See-Mode Augmented Reporting Tool, Breast (SMART-B)See-Mode Technologies Pty, Ltd.Jul 28, 2026Traditional
K260714MammoScreen® (5)TherapixelJun 26, 2026Special
K253825Saige-DxDeepHealth, Inc.Jun 15, 2026Traditional
K253682DeepHealth ProstateAIQuantib B.V.Apr 29, 2026Traditional
K260320Lunit INSIGHT MMG (v1.1.10)Lunit, Inc.Apr 23, 2026Special
K253796Lunit INSIGHT DBT (V1.2)Lunit, Inc.Mar 26, 2026Traditional
K251474Median LCS (internal name) / eyonis LCS (trade name) (1.0)Median TechnologiesFeb 6, 2026Traditional
From FDA’s 510(k) database, as of Oct 29, 2026Export CSV (100 rows free · all 40 with a free account)

Clearances by year

40 QDQ 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.

YearClearancesMedian days to decision
2026 (so far)10154
20255216
20247153
20232149
20224131
20215169
20203173
2019290
20182122

Who submits

16 applicants cleared a QDQ device since 2011. 35% of the clearances went to applicants in United States, then Netherlands (20%), France (15%) and South Korea (15%). By type: Traditional 83% and Special 18%.

ApplicantClearances since 2011
Screenpoint Medical B.V.7
DeepHealth, Inc.5
Lunit, Inc.5
Therapixel5
Hologic, Inc.4
Icad, Inc.4
BeamWorks, Inc.1
Median Technologies1

How FDA classifies it

Class II (special controls). The special controls for this device are:

(1) Design verification and validation must include:

(i) A detailed description of the image analysis algorithm, including a description of the algorithm inputs and outputs, each major component or block, how the algorithm and output affects or relates to clinical practice or patient care, and any algorithm limitations.

(ii) A detailed description of pre-specified performance testing protocols and dataset(s) used to assess whether the device will provide improved assisted-read detection and diagnostic performance as intended in the indicated user population(s), and to characterize the standalone device performance for labeling. Performance testing includes standalone test(s), side-by-side comparison(s), and/or a reader study, as applicable.

(iii) Results from standalone performance testing used to characterize the independent performance of the device separate from aided user performance. The performance assessment must be based on appropriate diagnostic accuracy measures (e.g., receiver operator characteristic plot, sensitivity, specificity, positive and negative predictive values, and diagnostic likelihood ratio). Devices with localization output must include localization accuracy testing as a component of standalone testing. The test dataset must be representative of the typical patient population with enrichment made only to ensure that the test dataset contains a sufficient number of cases from important cohorts (e.g., subsets defined by clinically relevant confounders, effect modifiers, concomitant disease, and subsets defined by image acquisition characteristics) such that the performance estimates and confidence intervals of the device for these individual subsets can be characterized for the intended use population and imaging equipment.

(iv) Results from performance testing that demonstrate that the device provides improved assisted-read detection and/or diagnostic performance as intended in the indicated user population(s) when used in accordance with the instructions for use. The reader population must be comprised of the intended user population in terms of clinical training, certification, and years of experience. The performance assessment must be based on appropriate diagnostic accuracy measures (e.g., receiver operator characteristic plot, sensitivity, specificity, positive and negative predictive values, and diagnostic likelihood ratio). Test datasets must meet the requirements described in paragraph (b)(1)(iii) of this section.

(v) Appropriate software documentation, including device hazard analysis, software requirements specification document, software design specification document, traceability analysis, system level test protocol, pass/fail criteria, testing results, and cybersecurity measures.

(2) Labeling must include the following:

(i) A detailed description of the patient population for which the device is indicated for use.

(ii) A detailed description of the device instructions for use, including the intended reading protocol and how the user should interpret the device output.

(iii) A detailed description of the intended user, and any user training materials or programs that address appropriate reading protocols for the device, to ensure that the end user is fully aware of how to interpret and apply the device output.

(iv) A detailed description of the device inputs and outputs.

(v) A detailed description of compatible imaging hardware and imaging protocols.

(vi) Warnings, precautions, and limitations must include situations in which the device may fail or may not operate at its expected performance level (e.g., poor image quality or for certain subpopulations), as applicable.

(vii) A detailed summary of the performance testing, including test methods, dataset characteristics, results, and a summary of sub-analyses on case distributions stratified by relevant confounders, such as anatomical characteristics, patient demographics and medical history, user experience, and imaging equipment.

From 21 CFR 892.2090. Special controls are the requirements a 510(k) must show it meets.

Standards

21 CFR 892.2090 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent QDQ clearances declared.

Ask about QDQ

US FDA devices: 510(k), De Novo, guidance, 21 CFR

Questions about QDQ

What is FDA product code QDQ?

Product code QDQ, “Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer” in FDA's classification database, is a Class II device type under 21 CFR 892.2090 (radiological computer-assisted detection and diagnosis software), reviewed by FDA's Radiology panel. FDA's 510(k) database lists 40 clearances under QDQ, 40 of them since 2011.

How many 510(k) clearances are there under QDQ?

FDA’s 510(k) database listed 40 clearances under QDQ as of Oct 29, 2026, 40 of them decided since 2011; the most recent decision was Sep 14, 2026. The Predicate Finder searches the live database.

How long does FDA take to clear a QDQ 510(k)?

For the 19 QDQ clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 159 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.

Which companies have the most QDQ clearances?

Since 2011: Screenpoint Medical B.V. (7), DeepHealth, Inc. (5), Lunit, Inc. (5), Therapixel (5) and Hologic, Inc. (4). 16 applicants have cleared a QDQ device in that time.

Sources

  1. FDA product classification: QDQ · Product Classification database
  2. 21 CFR 892.2090: Radiological computer-assisted detection and diagnosis software · eCFR, as of Oct 27, 2026
  3. openFDA 510(k) query for QDQ · run Oct 29, 2026
  4. 510(k) Premarket Notification database · FDA, accessdata.fda.gov
Follow QDQGet an email when FDA clears, recalls or publishes guidance for QDQ devices.

Know what FDA already cleared.